Status:
RECRUITING
Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Lead Sponsor:
Invirsa, Inc.
Conditions:
Non-center Involved Diabetic Macular Edema
Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR \[Part 1\] and ...
Eligibility Criteria
Inclusion
- Key
- Male or female subjects ≥ 18 years of age and \< 76 years of age
- Diagnosed with diabetes (Type 1 or 2) with hemoglobin A1c ≤ 12.0%
- Study eye must have NCIDME (Part 1) or CIDME (Part 2)
- Study eye must be moderate to severe NPDR
- Key
Exclusion
- Prior laser treatment for DR in the study eye within 12 months from Screening Visit
Key Trial Info
Start Date :
September 7 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2025
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06599684
Start Date
September 7 2024
End Date
August 1 2025
Last Update
April 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MedTrials, Inc.
Dallas, Texas, United States, 75204